Cargando…
Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins
Human papillomavirus (HPV) vaccines confer protection against the oncogenic genotypes HPV16 and HPV18 through the generation of type-specific neutralizing antibodies raised against the constituent virus-like particles (VLP) based upon the major capsid proteins (L1) of these genotypes. The vaccines a...
Autores principales: | Bissett, Sara L., Mattiuzzo, Giada, Draper, Eve, Godi, Anna, Wilkinson, Dianna E., Minor, Philip, Page, Mark, Beddows, Simon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228199/ https://www.ncbi.nlm.nih.gov/pubmed/25203446 http://dx.doi.org/10.1016/j.vaccine.2014.07.116 |
Ejemplares similares
-
Cross-neutralizing antibodies elicited by the Cervarix(®) human papillomavirus vaccine display a range of Alpha-9 inter-type specificities()
por: Bissett, Sara L., et al.
Publicado: (2014) -
The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies
por: Bissett, Sara L., et al.
Publicado: (2016) -
Amino acid sequence diversity of the major human papillomavirus capsid protein: Implications for current and next generation vaccines()
por: Ahmed, Amina I., et al.
Publicado: (2013) -
A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix(®) and Gardasil(®) Human Papillomavirus Vaccines in 12-15 Year Old Girls
por: Draper, Eve, et al.
Publicado: (2013) -
Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera
por: Draper, Eve, et al.
Publicado: (2011)